ACRV:NSD-Acrivon Therapeutics Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 6.61

Change

0.00 (0.00)%

Market Cap

USD 0.20B

Volume

0.62M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.49 (-0.31%)

USD 122.24B
REGN Regeneron Pharmaceuticals Inc

-18.30 (-1.71%)

USD 115.08B
MRNA Moderna Inc

-1.27 (-1.04%)

USD 51.07B
ALNY Alnylam Pharmaceuticals Inc

+1.83 (+0.75%)

USD 28.20B
ARGX argenx NV ADR

-0.94 (-0.21%)

USD 26.78B
BNTX BioNTech SE

-2.14 (-2.59%)

USD 20.40B
BGNE BeiGene Ltd

-0.86 (-0.59%)

USD 17.50B
GMAB Genmab AS

-0.09 (-0.35%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-1.75 (-2.05%)

USD 15.98B
RPRX Royalty Pharma Plc

+0.09 (+0.34%)

USD 15.90B

ETFs Containing ACRV

CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.14 (+1.00%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.35% 82% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.35% 82% B 89% A-
Trailing 12 Months  
Capital Gain -51.58% 36% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.58% 36% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -19.95% 31% F 18% F
Dividend Return -19.95% 31% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.14% 87% B+ 63% D
Risk Adjusted Return -68.45% 24% F 14% F
Market Capitalization 0.20B 58% F 49% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector